[Fulminant hepatitis induced by paracetamol at a therapeutic dose favoured by the ingestion of enzyme inducers in a patient with liver cirrhosis].
Hastier
P
P
Paolini
O
O
Demarquay
J F
JF
Caroli-Bosc
F X
FX
Chichmanian
R M
RM
Saint-Paul
M C
MC
Delmont
J
J
D000082:Acetaminophen / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D003866:Depressive Disorder / Q000139:chemically induced / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D000431:Ethanol / Q000009:adverse effects; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D008104:Liver Cirrhosis, Alcoholic / Q000150:complications*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D013375:Substance Withdrawal Syndrome / Q000150:complications
D000082:Acetaminophen; D018712:Analgesics, Non-Narcotic; D000431:Ethanol; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors
Hépatite fulminate au paracétamol à dose thérapeutique favorisée par la prise d'inducteurs enzymatiques chez une malade atteinte de cirrhose.